1. Home
  2. Analysis
  3. Methenamine-hippurate
  4. Xarelto

Methenamine hippurate and Xarelto drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among 18 people who take Methenamine hippurate and Xarelto. Common interactions include coagulopathy among females, and dyspnoea among males.

The phase IV clinical study analyzes what interactions people who take Methenamine hippurate and Xarelto have. It is created by eHealthMe based on reports from the FDA, and is updated regularly. You may use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 700+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Sep, 28, 2023

18 people who take Methenamine hippurate and Xarelto together, and have interactions are studied.

What is Methenamine hippurate?

Methenamine hippurate has active ingredients of methenamine hippurate. It is used in urinary tract infection. Currently, eHealthMe is studying from 990 Methenamine hippurate users.

What is Xarelto?

Xarelto has active ingredients of rivaroxaban. It is used in atrial fibrillation/flutter. Currently, eHealthMe is studying from 206,341 Xarelto users.

Number of Methenamine hippurate and Xarelto reports submitted per year:

Methenamine hippurate and Xarelto drug interactions.

Common Methenamine Hippurate and Xarelto drug interactions by gender *:

female:

  1. Coagulopathy
  2. Lower gastrointestinal haemorrhage
  3. Nausea
  4. Transient ischaemic attack
  5. Abdominal discomfort
  6. Asthma
  7. Bladder prolapse
  8. Blood chloride increased
  9. Blood pressure increased
  10. Blood urea increased

male:

  1. Dyspnoea
  2. Gastritis
  3. Eye swelling
  4. Fall
  5. Gallbladder disorder
  6. Gingival swelling
  7. Hallucination, visual
  8. Hypotension
  9. Infection
  10. Lip swelling

Common Methenamine Hippurate and Xarelto drug interactions by age *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

n/a

60+:

  1. Coagulopathy
  2. Lower gastrointestinal haemorrhage
  3. Gallbladder disorder
  4. Headache
  5. Limb injury
  6. Myocarditis
  7. Nausea
  8. Transient ischaemic attack
  9. Dyspnoea
  10. Gastritis

Common conditions people have *:

  1. Sleep Disorder: 4 people, 22.22%
  2. Pain: 3 people, 16.67%
  3. Hypersensitivity: 2 people, 11.11%
  4. Stroke (sudden death of a portion of the brain cells due to a lack of oxygen): 2 people, 11.11%
  5. Parkinson's Disease: 2 people, 11.11%
  6. Cough: 2 people, 11.11%
  7. Deep Venous Thrombosis (blood clot in a major vein that usually develops in the legs and/or pelvis): 2 people, 11.11%
  8. Delusion (a false belief or opinion): 1 person, 5.56%
  9. Hallucinations (sensations that appear real but are created by your mind): 1 person, 5.56%
  10. Gout (uric acid crystals building up in the body): 1 person, 5.56%

* Approximation only. Some reports may have incomplete information.

Do you take Methenamine hippurate and Xarelto?

Personalize this study to your gender and age

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

Drug side effects by duration, gender and age:

Common Methenamine hippurate drug interactions:

Browse interactions between Methenamine hippurate and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Xarelto drug interactions:

Browse interactions between Xarelto and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on methenamine hippurate and rivaroxaban (the active ingredients of Methenamine hippurate and Xarelto, respectively), and Methenamine hippurate and Xarelto (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study. Patients in the study may take other drugs besides Methenamine hippurate and Xarelto.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 700+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2023 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.